323 related articles for article (PubMed ID: 34003354)
21. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
22. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
23. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
[TBL] [Abstract][Full Text] [Related]
24. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
Dalle Ore C; Coleman C; Gupta N; Mueller S
Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG).
Giagnacovo M; Antonelli M; Biassoni V; Schiavello E; Warmuth-Metz M; Buttarelli FR; Modena P; Massimino M
Childs Nerv Syst; 2020 Apr; 36(4):697-704. PubMed ID: 31848724
[TBL] [Abstract][Full Text] [Related]
26. Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma.
Lober RM; Cho YJ; Tang Y; Barnes PD; Edwards MS; Vogel H; Fisher PG; Monje M; Yeom KW
J Neurooncol; 2014 Mar; 117(1):175-82. PubMed ID: 24522717
[TBL] [Abstract][Full Text] [Related]
27. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.
Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y
Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332
[TBL] [Abstract][Full Text] [Related]
28. MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma.
Jaimes C; Vajapeyam S; Brown D; Kao PC; Ma C; Greenspan L; Gupta N; Goumnerova L; Bandopahayay P; Dubois F; Greenwald NF; Zack T; Shapira O; Beroukhim R; Ligon KL; Chi S; Kieran MW; Wright KD; Poussaint TY
AJNR Am J Neuroradiol; 2020 May; 41(5):874-881. PubMed ID: 32381545
[TBL] [Abstract][Full Text] [Related]
29. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
30. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
[TBL] [Abstract][Full Text] [Related]
31. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
Buczkowicz P; Bartels U; Bouffet E; Becher O; Hawkins C
Acta Neuropathol; 2014 Oct; 128(4):573-81. PubMed ID: 25047029
[TBL] [Abstract][Full Text] [Related]
32. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements.
Chen H; Hu W; He H; Yang Y; Wen G; Lv X
Eur J Radiol; 2019 May; 114():152-159. PubMed ID: 31005167
[TBL] [Abstract][Full Text] [Related]
35. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
Hoeman CM; Cordero FJ; Hu G; Misuraca K; Romero MM; Cardona HJ; Nazarian J; Hashizume R; McLendon R; Yu P; Procissi D; Gadd S; Becher OJ
Nat Commun; 2019 Mar; 10(1):1023. PubMed ID: 30833574
[TBL] [Abstract][Full Text] [Related]
36. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
37. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
38. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
39. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.
Thomas L; Smith N; Saunders D; Zalles M; Gulej R; Lerner M; Fung KM; Carcaboso AM; Towner RA
J Transl Med; 2020 Nov; 18(1):424. PubMed ID: 33168005
[TBL] [Abstract][Full Text] [Related]
40. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
